Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum | New

TAMPA, Fla .– (BUSINESS WIRE) – November 23, 2021–

Oragenics, Inc. (US NYSE: OGEN) (“Oragenics” or the “Company”) has announced that the Annual Meeting of Shareholders of the Company (the “Annual Meeting”) on November 22, 2021 at 9:00 am has been called and adjourned, without any business taking place. be conducted, due to the absence of the required quorum.

The quorum is made up of the majority of shares with voting rights. There was less than a majority of voting shares present, either in person or by proxy at this meeting. The annual meeting therefore did not have a quorum and the meeting was adjourned at 4:00 p.m. (Eastern Time) on Tuesday, January 25, 2022 at the offices of Shumaker, Loop, & Kendrick, Bank of America Plaza, 101 E Kennedy Blvd., Suite 2800, Tampa, FL 33602 to grant additional time for shareholders of the Company to vote on the proposals set out in the Company’s definitive proxy statement filed with the United States Securities and Exchange Commission (the “SEC”) on October 13, 2021.

During the current adjournment, the Company plans to continue to solicit the votes of its shareholders with respect to the proposals set out in the Company’s proxy circular. As set out in the proxy statement, the Company has engaged an agent, Alliance Advisors, to assist management in obtaining the votes adequate to achieve the required quorum of at least a majority of the outstanding common shares.

Only registered shareholders, on the registration date, October 1, 2021, have the right to vote and are called to vote. At the time of the adjournment of the Annual Meeting, proxies had been submitted by shareholders representing approximately 40% of the outstanding common shares of the Company and entitled to vote at the Annual Meeting. Proxies previously submitted in respect of the annual meeting will be voted on at the adjourned annual meeting unless they are properly revoked, and shareholders who have already submitted a proxy or who have voted otherwise have not to take action.

The Company encourages all shareholders of record on October 1, 2021, who have not yet voted, to do so by January 24, 2022 at 11:59 p.m. EST. Shareholders who have questions or need assistance in completing a proxy or voting instruction form or who do not have the required documents, can contact Alliance Advisors, using the following contact details 200 Broadacres Drive, 3rd Fl ., Bloomfield, NJ 07003, Phone: Toll Free: 1-855-723-7816 and outside North America: 1-973-873-7700 Email: [email protected]

If the number of additional common shares voted on at the adjourned annual meeting is not sufficient to achieve a quorum, the Company may request to adjourn the annual meeting again, which will cause the Company to incur additional costs.

Important information

These documents may be considered as solicitation documents with respect to the Annual Meeting which will be reconvened and to be held on January 25, 2022. In connection with the Annual Meeting, the Company has filed a solicitation circular DECLARATION OF DEFINITIVE PROXY WITH THE SEC on October 13, 2021. BEFORE MAKING ANY VOTING DECISIONS, SECURITYHOLDERS ARE INVITED TO READ THE DEFINITIVE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE SECURITY ‘ANNUAL MEETING. The definitive proxy circular has been mailed to shareholders who are entitled to vote at the annual meeting. No changes were made to the proposals submitted to the vote of the shareholders at the Annual Meeting. The Company’s proxy statement and any other documents filed by the Company with the SEC can be obtained free of charge from the SEC’s website at sec.gov or from the Company’s website https: // ir .oragenics.com / all-sec-filings.

About Oragenics, Inc.

Oragenics, Inc. is a developmental company dedicated to the control of infectious diseases, including coronaviruses and multidrug resistant organisms. Its flagship product is Terra CoV-2, a vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. Terra CoV-2 program builds on advanced coronavirus protein research licensed from the National Institute of Health and the National Research Council of Canada with a focus on problem solving in the chain supply and providing more patient-friendly delivery, such as intranasal. Its lantibiotics program offers a new class of antibiotics against infectious diseases that have developed resistance to commercial antibiotics.

For more information about Oragenics, please visit www.oragenics.com.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20211123005657/en/

CONTACT: Oragenics, Inc.

Michael Sullivan, Chief Financial Officer


[email protected]


LHA Investor Relations

Kim golodetz


[email protected]



SOURCE: Oragenics, Inc.

Copyright Business Wire 2021.

PUB: 23/11/2021 08:30 / DISC: 23/11/2021 08:32


Copyright Business Wire 2021.

Source link

Comments are closed.